IL1B and Behcet disease: We also found that, whereas blockade of IL-6 (BD+anti-IL-6+LT) increased IL-1β and damage in non-steatotic livers from DBDs more than in the BD+LT group, the inhibition of the action of both IL-6 and IL-1β (BD+anti-IL-6+IL-1ra+LT) gave rise to parameters that reflected liver damage and inflammation (Figures 2, 3), which were lower than those of the BD+LT group.